Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Non-Current Deffered Revenue (2017 - 2025)

Historic Non-Current Deffered Revenue for Ascendis Pharma A (ASND) over the last 9 years, with Q3 2025 value amounting to $4.9 million.

  • Ascendis Pharma A's Non-Current Deffered Revenue rose 90956.52% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 million, marking a year-over-year increase of 90956.52%. This contributed to the annual value of $5.4 million for FY2024, which is 1545.25% down from last year.
  • As of Q3 2025, Ascendis Pharma A's Non-Current Deffered Revenue stood at $4.9 million, which was up 90956.52% from -$3.9 million recorded in Q2 2025.
  • Ascendis Pharma A's 5-year Non-Current Deffered Revenue high stood at $14.5 million for Q4 2022, and its period low was -$3.9 million during Q2 2025.
  • In the last 5 years, Ascendis Pharma A's Non-Current Deffered Revenue had a median value of $3.4 million in 2021 and averaged $3.7 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Non-Current Deffered Revenue surged by 3114024.28% in 2022, and later crashed by 33234.38% in 2025.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Non-Current Deffered Revenue stood at $3.4 million in 2021, then surged by 327.66% to $14.5 million in 2022, then crashed by 55.86% to $6.4 million in 2023, then decreased by 16.53% to $5.3 million in 2024, then decreased by 8.98% to $4.9 million in 2025.
  • Its Non-Current Deffered Revenue stands at $4.9 million for Q3 2025, versus -$3.9 million for Q2 2025 and $1.3 million for Q1 2025.